Publications
11
Citations
85
Est. group size
~2
Recurring co-author estimate
Active years
6
Publishing since 2020
Emily Stahl's research focuses on the molecular biology of cancer, particularly how defects in DNA repair pathways (such as the Fanconi anemia/BRCA pathway) can be exploited alongside cell-division proteins like Aurora kinase and PLK1 to selectively limit tumor growth. Related work has also examined RNA splicing patterns in Ewing sarcoma, a type of bone cancer. This research aims to identify vulnerabilities in cancer cells that could inform future targeted therapies.
Publication output was minimal before 2020 but has increased since 2022, averaging about 2 publications per year over the last five years.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- 5 Aurora kinase inhibition synergizes with Fanconi anemia pathway defects to limit tumorigenesis
Journal of Clinical and Translational Science · 2025
- PLK1 Acts in Homologous Recombinatorial Repair and in Mitosis As Synthetically Lethal with the Fanconi Anemia/BRCA Pathway
Blood · 2024
- Comprehensive profiling of mRNA splicing indicates that GC content signals altered cassette exon inclusion in Ewing sarcoma
NAR Cancer · 2022
- JCI Insight×2
- Blood×2
- Cancer Research×2
- European Journal of Medicinal Chemistry×1
- ACS Medicinal Chemistry Letters×1
- Donna Bucci
Medicine · The Ohio State University
- Jean Truxall
Medicine · The Ohio State University
- James Ropa
Medicine · Indiana University
- Alice S. Mims
Medicine · The Ohio State University
- Ann-Kathrin Eisfeld
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile